Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal, Canada

Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has concluded audit of the Radiopharmaceutical manufacturing facility on April, 23, 2024 at Montreal, Canada of Jubilant Draximage Inc. ('Company'), a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.

The USFDA has issued 5 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 682.55 as compared to the previous close of Rs. 684.70. The total number of shares traded during the day was 10440 in over 552 trades.

The stock hit an intraday high of Rs. 690.00 and intraday low of 679.00. The net turnover during the day was Rs. 7126326.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 USFDA Audit Radiopharma ManufacturingFacility JubilantDraximage